Почетна › Немалоклетни карцином плућа › Пенсилванија
Kliničke studije za Немалоклетни карцином плућа u državi Пенсилванија
100 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u državi Пенсилванија.
Gradovi u državi Пенсилванија
- Philadelphia49 студија
- Pittsburgh47 студија
- Allentown15 студија
- York14 студија
- Harrisburg12 студија
- Reading8 студија
- Lancaster7 студија
- Erie6 студија
- Scranton6 студија
- Chambersburg6 студија
- Hazleton4 студија
- New Castle4 студија
- Williamsport3 студија
Zvanični tekst studije (na engleskom)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Alliance Cancer Specialists - Media, Media
- Guthrie Medical Group, Sayre
Тражи се учесникФаза 3
Узраст од 18 до 100 · Оба пола · Ажурирано 13. 11. 2026. · NCT05920356Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Hospital of the University of Pennsylvania, Philadelphia
- West Penn Allegheny Health, Pittsburgh
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07100080A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111), Lancaster
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07190248Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Bryn Mawr Hospital, Bryn Mawr
- и још 14
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Lehigh Valley Hospital-Cedar Crest, Allentown
- UPMC Altoona, Altoona
- UPMC-Heritage Valley Health System Beaver, Beaver
- и још 52
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04267848A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134), Lancaster
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06345729A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Univ of Pennsylvania, Abramson Cancer Center, Philadelphia
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07020221A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Penn State Milton S. Hershey Medical Center-Penn State Cancer Institute ( Site 0059), Hershey
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06312137A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
- UPMC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06868485Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Local Institution - 0487, Easton
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07680790Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Hershey
- Research Site, Lancaster
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07291037LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Abramson Cancer Center, Philadelphia
- AHN Cancer Center, Pittsburgh
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06216301A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- St. Lukes Hospital and Health Network ( Site 0186), Bethlehem
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06623422A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Perelman Center for Advanced Medicine ( Site 3205), Philadelphia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07513376A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
- Local Institution - 0504, Philadelphia
- Local Institution - 0520, Philadelphia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06561386Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Lehigh Valley Health Network, Allentown
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT04198766A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Alliance Cancer Specialists, PC, Bensalem
- Consultants in Medical Oncology and Hematology, P.C., Broomall
- Alliance Cancer Specialists, PC, Doylestown
- и још 5
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07144280A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- St. Luke's University Health Network, Bethlehem
- Allegheny Cancer Center, Pittsburgh
- Reading Hospital - McGlinn Cancer Institute, West Reading
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06793215Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- Jefferson Hospital Northeast, Philadelphia
- AHN Allegheny General Hospital, Pittsburgh
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06890598A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06706076Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Alliance Cancer Specialist, Doylestown
- Allegheny Health Network, Pittsburgh
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- WellSpan Medical Oncology and Hematology, Chambersburg
- и још 13
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Cancer Care Associates of York (site 206), York
Тражи се учесникФаза 1/2
Узраст од 18 до 80 · Оба пола · Ажурирано 4. 11. 2026. · NCT03556228A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Alliance Cancer Specialists, PC, Horsham
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06119581Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07397338Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Bryn Mawr Hospital, Bryn Mawr
- и још 5
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT03191149A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Fox Chase Cancer Center, Philadelphia
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07542704Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06060613A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- UPMC-Heritage Valley Health System Beaver, Beaver
- Carlisle Regional Cancer Center, Carlisle
- UPMC Hillman Cancer Center Erie, Erie
- и још 17
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07293247A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- University of Pennsylvania, Philadelphia
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06667908A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Sydney Kimmel Cancer Center, Philadelphia
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06720987Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Fox Chase Cancer Center, Philadelphia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07185997Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Veterans Affairs Pittsburgh Healthcare System - University Drive Campus, Pittsburgh
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT04613596First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- Thomas Jefferson University Research Facility, Philadelphia
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06043817KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT04165070KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT04165798Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Fox Chase Cancer Center, Philadelphia
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT05098132A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Hershey
- Research Site, York
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06692738Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- St Luke's University Health Network ( Site 0017), Bethlehem
- Thomas Jefferson University - Clinical Research Institute ( Site 0147), Philadelphia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06422143A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
- UPMC, Pittsburgh
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06774963Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.